Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 10/20 | 0.61 |
| ▸ | GRIN1 | Q05586 | 9/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 3/20 | 0.43 |
| ▸ | DRD4 | P21917 | 3/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6001498 | 1.00 | GRIN2B (0.61) | GRIN2BGRIN1THRBGAANPC1 | |
| SCHEMBL6001504 | 1.00 | GRIN2B (0.61) | GRIN2BGRIN1THRBGAANPC1 | |
| SCHEMBL5235290 | 0.90 | GRIN1 (0.62) | GRIN2BGRIN1THRBGAANPC1 | |
| SCHEMBL5235309 | 0.90 | GRIN1 (0.62) | GRIN2BGRIN1THRBGAANPC1 | |
| SCHEMBL5235300 | 0.90 | GRIN1 (0.62) | GRIN2BGRIN1THRBGAANPC1 | |
| SCHEMBL5237195 | 0.84 | GRIN1 (0.84) | GRIN2BGRIN1THRBGAANPC1 | |
| SCHEMBL8313749 | 0.82 | GRIN1 (0.74) | GRIN2BGRIN1GAAPKMTSHR | |
| SCHEMBL8313723 | 0.76 | GRIN1 (1.00) | GRIN2BGRIN1THRBGAAPKM | |
| SCHEMBL5999878 | 0.75 | FUCA1 (0.58) | NPC1CYP2D6 | |
| SCHEMBL5973803 | 0.75 | FUCA1 (0.58) | NPC1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160853-A1 | 2-[(4-Benzyl)-1-piperidinyl)methyl]benzimidazole-5-ol derivatives as nr2b receptor antagonists | MERCK & CO., INC. | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160853-A1 | 2-[(4-Benzyl)-1-piperidinyl)methyl]benzimidazole-5-ol derivatives as nr2b receptor antagonists | GRIN2B, GRIN1, GRIN2A | GRIN2B 1/4885GRIN1 2/4885THRB 834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.